“Pharmacological activators and inhibitors of Kv3.1 potassium currents” (Brown et al.).
Comments are closed.
Autifony Therapeutics aims to develop new drugs to treat serious disorders of the central nervous system using pioneering science.
Scientific publications can be found here as well as information on Voltage-gated ion channels as therapeutics targets and Kv3 ion channels.
Clinical stage programmes for schizophrenia and Fragile X, and earlier stage programmes focused on Hearing disorders and Alzheimer’s Disease.